<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853112</url>
  </required_header>
  <id_info>
    <org_study_id>A7331009</org_study_id>
    <nct_id>NCT00853112</nct_id>
  </id_info>
  <brief_title>A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension</brief_title>
  <official_title>A Phase 2a, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study Investigating The Dose-Response Of PF-00489791 On Acute Hemodynamics In Subjects With Idiopathic And Familial Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pfizer decided to stop this trial early upon Stage 1 completion due to change in PF-00489791
      development and not as a result of safety concerns for PF-00489791. Date of termination
      (LSLV) occurred on July 28, 2010.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in PVRI</measure>
    <time_frame>Day 1, 4 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hourly changes from baseline in cardiac index, mean PAP and other hemodynamic parameters</measure>
    <time_frame>Day 1, up to 4 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in PaO2 and PaCO2</measure>
    <time_frame>Day 1, up to 4 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of PF-00489791 and sildenafil</measure>
    <time_frame>up to Day 3 - 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of PF-00489791 after a single dose administration as assessed by incidence of treatment-emergent adverse events, changes from baseline in clinical laboratory tests, and ECG</measure>
    <time_frame>up to Day 3 - 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Greatest reduction and hourly changes from baseline in PVRI</measure>
    <time_frame>Day 1, up to 4 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change, greatest reduction and hourly changes from baseline in SVRI</measure>
    <time_frame>Day 1, up to 4 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of PF-00489791 after a single dose administration as assessed by incidence of treatment-emergent adverse events</measure>
    <time_frame>up to Day 10 - 14</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>PF-00489791 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-00489791 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-00489791 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-00489791 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-00489791 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Observational comparator arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00489791</intervention_name>
    <description>tablet form, 1 mg, single dose (Day 1)</description>
    <arm_group_label>PF-00489791 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00489791</intervention_name>
    <description>tablet form, 2 mg, single dose (Day 1)</description>
    <arm_group_label>PF-00489791 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00489791</intervention_name>
    <description>tablet form, 4 mg, single dose (Day 1)</description>
    <arm_group_label>PF-00489791 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00489791</intervention_name>
    <description>tablet form, 10 mg, single dose (Day 1)</description>
    <arm_group_label>PF-00489791 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00489791</intervention_name>
    <description>tablet form, 20 mg, single dose (Day 1)</description>
    <arm_group_label>PF-00489791 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet form, single dose (Day 1)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>tablet form, 20 mg, single dose (Day 1)</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic or familial pulmonary arterial hypertension (PAH)

          -  Mean PAP at least 25 mm Hg, PCWP &lt; 15 mm Hg at rest

          -  For females of child-bearing potential negative pregnancy test at screening and use
             of contraception during the study and 4 weeks after its completion

          -  Signed and dated informed consent

          -  Willingness to comply with the study plan and procedures

        Exclusion Criteria:

          -  pulmonary arterial hypertension (PAH)other than idiopathic or familial

          -  For females, pregnancy or lactation

          -  Use of specific PAH treatments, potent CYP3A4 inhibitors, protease inhibitors, alpha
             blockers or arginine 30 days prior tio randomization and during the study

          -  Change of dose or class of standard background PAH therapy, i.e. oxygen, calcium
             channel blockers, digoxin, diuretics 30 days prior tio randomization and during the
             study

          -  Large shift in altitude (defined as &gt;5000 feet or 1524 meters) during 90 days prior
             to baseline visit and/or during the study visit

          -  Subjects with intracardiac shunts and/or serious heart, lung or other health
             conditions

          -  HIV positive subjects

          -  Subjects participating in another clinical trial with an investigational drug or
             device

          -  Subjects with degenerative retinal disorders, history of non-arteritic anterior
             ischemic optic neuropathy or untreated proliferative diabetic retinopathy

          -  Allergies and previous intolerance of PDE5 inhibitors

          -  Alcohol or drug abuse

          -  Blood donation during the study, or 1 month before or after the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pardesh</state>
        <zip>500 063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tirupati</city>
        <state>Andhra Pardesh</state>
        <zip>517 507</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zuerich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>India</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7331009&amp;StudyName=A%20Research%20Study%20To%20Assess%20The%20Effectiveness%20And%20Safety%20Of%20Different%20Doses%20Of%20Oral%20PF-00489791%20In%20The%20Treatment%20Of%20Adult%20Patients%20Wi</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 27, 2012</lastchanged_date>
  <firstreceived_date>February 27, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>March 27, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAH pulmonary hypertension pulmonary arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
